Lanreotide subcutaneous injection – Cipla — Medica

Initial criteria

• Patient meets ONE of the following: has had an inadequate response to surgery and/or radiotherapy; OR is not an appropriate candidate for surgery and/or radiotherapy; OR is experiencing negative effects due to tumor size (e.g., optic nerve compression)
• Patient has (or had) a pre-treatment insulin-like growth factor-1 (IGF-1) level above the upper limit of normal based on age and gender for the reporting laboratory
• Medication is prescribed by or in consultation with an endocrinologist

Approval duration

1 year